Can You Support NAD+ Without an IV? The Science Behind Longevita

If you've searched "NAD+ therapy" recently, you've probably landed on a clinic page advertising a two-hour infusion drip, often for a few hundred dollars a session. It's easy to walk away thinking a needle is the only serious way to raise NAD+. It isn't.

The molecule your cells actually need, nicotinamide adenine dinucleotide, or NAD+, is not something you inject and expect to work like a light switch. It's a coenzyme your body already knows how to build for itself, provided it has the right raw materials. That's the entire premise behind an oral NAD+ precursor formulation like Longevita: give the body's own biosynthetic pathway the inputs it needs, consistently, every day, rather than trying to force a large dose of the finished molecule into the bloodstream on an occasional clinic visit.

This article breaks down what NAD+ actually is, why it declines with age, and what the peer-reviewed evidence says about supporting it through daily oral supplementation rather than IV infusion.

What NAD+ Actually Does  And Why It Falls With Age?

NAD+ is a coenzyme involved in hundreds of metabolic reactions. It's essential for energy production and cellular repair systems, acting as a substrate for NAD+-dependent enzymes including sirtuins, which regulate metabolism, stress response and longevity; PARPs, which consume NAD+ to repair damaged genetic material; and CD38, an immune enzyme that degrades NAD+ and drives its age-related depletion (Covarrubias et al., 2020).

The problem is that this system doesn't stay stable over a lifetime. Ageing is accompanied by a progressive decline in tissue and cellular NAD+ levels, which is causally linked to multiple age-related conditions including neurodegeneration, sarcopenia, metabolic disease and frailty (Fang et al., 2017). We've covered the mechanics of this decline, including the role of the CD38 enzyme and chronic low-grade inflammation, in more depth in our article on why NAD+ falls with age and the role of CD38 and inflammaging.

This is precisely the gap Longevita is built to address. NAD+ levels decline with ageing, and Longevita provides NAD+ precursors, nicotinamide riboside and niacinamide, to boost healthy NAD+ availability, which helps maintain cellular energy metabolism and repair-related enzyme function, according to the brand's own published science.

Why You Don't Need an IV to Raise NAD+?

The core biological reason IV infusion isn't the only path to NAD+ support is simple: your body was never designed to absorb finished NAD+ through the gut in the first place. NAD+ is a relatively large, charged molecule. What actually crosses into your cells and gets converted into usable NAD+ are smaller precursor molecules, chiefly nicotinamide riboside (NR) and nicotinamide (niacinamide), that your cells process through a well-mapped biosynthetic route called the salvage pathway.

Nicotinamide Riboside: A Direct, Efficient Route to NAD+

Nicotinamide riboside chloride is the chloride salt of nicotinamide riboside, a vitamin B3 analogue comprising nicotinamide bound to a ribose moiety. Upon oral intake, it is absorbed and hydrolysed to nicotinamide, contributing to the body's nicotinamide pool and serving as a precursor for NAD+ biosynthesis (Covarrubias et al., 2020). NR enters cells and is phosphorylated by nicotinamide riboside kinases into nicotinamide mononucleotide (NMN), which is then converted into NAD+, a route that bypasses the rate-limiting NAMPT step that other precursors must pass through (Covarrubias et al., 2020). The European Food Safety Authority has confirmed that ingested NR chloride reliably yields nicotinamide, and ultimately NAD+, in humans.

The clinical data back this up directly. In an 8-week randomised, double-blind, placebo-controlled trial, healthy overweight adults given 100 to 1,000 mg per day of NR chloride showed dose-dependent increases in whole-blood NAD+  with the highest dose raising levels by roughly 142% over baseline within two weeks, sustained for the remainder of the study, and with no flushing or major adverse events reported (Conze et al., 2019).

In older adults specifically, a crossover study gave twelve men aged 70 to 80 a gram of NR chloride daily for three weeks. Muscle NAD+-related metabolites rose, RNA profiling revealed a shift away from inflammatory and mitochondrial stress signalling, and circulating inflammatory markers including IL-6, IL-2 and TNF-α fell significantly (Elhassan et al., 2019). This confirms that oral NR is not only bioavailable in aged human tissue, but also produces a measurable anti-inflammatory signature, all without a needle.

Nicotinamide: Sustaining the NAD+ Pool for the Long Term

Alongside NR, nicotinamide (niacinamide) feeds into NAD+ and NADP+ synthesis through the de novo, Preiss–Handler and salvage pathways, together forming what researchers describe as the broader "vitamin B3 metabolome" (Makarov et al., 2019). By sustaining cellular NAD+ pools, nicotinamide supports mitochondrial energy metabolism and ATP production, fuels DNA repair through PARP enzymes, regulates epigenetic and stress-response programmes via sirtuins, and maintains redox balance through NADPH-dependent antioxidant systems (Covarrubias et al., 2021).

One of the clearest demonstrations of this comes from DNA repair research. PARP enzymes rely on NAD+ as their sole fuel source to fix DNA strand breaks. When niacin is restricted in human skin cells, NAD+ falls, PARP activation after UV-like damage is blunted, and background DNA damage increases; restoring niacin reverses all of it (Benavente et al., 2012). In older inactive men, short-term nicotinic acid intake increased skeletal muscle mitochondrial respiration and boosted key components of the electron transport chain, directly increasing the muscle's capacity to produce ATP (Deane et al., 2024).

Together, NR and nicotinamide give a daily oral protocol two complementary entry points into the same NAD+ system: one optimised for a fast, efficient rise in NAD+ availability, the other optimised for sustaining that pool and reinforcing the DNA repair and antioxidant pathways NAD+ depends on. We've written more on how these two precursors work together in our article on NR vs nicotinamide and why Longevita uses both NAD+ precursors.

What About the "Bioavailability" Argument for IV Therapy?

The most common argument for IV NAD+ therapy is bioavailability: the idea that injecting NAD+ directly into the bloodstream guarantees near-complete absorption, while oral precursors face digestive losses. This is true as far as blood concentration goes. But blood concentration and cellular utilisation are not the same thing.

NAD+ itself is a large, charged molecule, and getting more of it into the bloodstream does not automatically mean more of it crosses into the cells where it is actually used. Oral precursors like NR and nicotinamide, by contrast, are converted into NAD+ through enzymatic steps your cells already run continuously as part of normal metabolism, the same salvage pathway your body has relied on for this purpose across its entire evolutionary history (Covarrubias et al., 2020). The randomised controlled trials on NR and nicotinamide summarised above are measuring exactly the endpoint that matters: sustained increases in the body's own NAD+ metabolome, achieved safely and repeatedly through daily oral dosing.

Why Daily Consistency Matters More Than a Single High Dose?

There's also a practical dimension to this that has nothing to do with biochemistry. Longevity outcomes are built on sustained physiological change across months and years, not a single high-concentration event. An IV drip is, by nature, episodic; it requires booking a clinic appointment, sitting through an infusion, and repeating the process on a recurring schedule to maintain any benefit.

A daily oral NAD+ precursor protocol is designed to work the opposite way. It integrates into an existing routine. Longevita is formulated as a single daily capsule, described on the brand's own site as beginning your journey to healthy ageing with "one daily ritual." The repeat-dose clinical data on NR reflects this design logic directly: the NAD+ elevation seen in the Conze et al. (2019) trial wasn't a one-time spike; it was measured and sustained across the full eight-week study period with continued daily dosing.

How Does Longevita's Formulation Approach NAD+ Support?

Longevita combines 12 evidence-backed ingredients in a single daily formulation designed to boost NAD+ levels and target cellular ageing across the body, according to the brand's published science. Rather than relying on one NAD+ precursor to do all the work, the formulation includes both nicotinamide riboside and niacinamide, giving it two distinct, complementary routes into NAD+ biosynthesis: the fast, NAMPT-independent path through NR, and the broader metabolic and DNA-repair support through nicotinamide.

This sits inside a wider formulation strategy that also targets mitochondrial function directly. Cellular energy and healthy ageing depend not just on raising NAD+, but on what mitochondria do with that energy once it's available, which is where mitochondrial antioxidants such as CoQ10 come in. We explore this complementary pathway in our article on CoQ10 and its role in supporting cellular energy and healthy ageing, which works alongside NAD+ precursors within Longevita's broader formulation to support mitochondrial ATP production and reduce oxidative stress system-wide.

Beyond NAD+ precursors, Longevita's formula also includes polyphenols such as pterostilbene and trans-resveratrol to support AMPK-related pathways, the body's key cellular energy sensor, along with antioxidants including lutein and CoQ10 to help strengthen the body's antioxidant network against oxidative stress from ageing, UV exposure and lifestyle factors, all delivered through a doctor-formulated, third-party tested capsule made in a GMP-certified, USFDA-registered facility in the UK.

Safety Considerations

Both core NAD+ precursors used in oral protocols carry a strong safety profile at researched doses. The 8-week NR chloride trial reported no flushing and no major adverse events even at 1,000 mg/day, with blood lipids and one-carbon metabolism remaining unchanged throughout the study (Conze et al., 2019). Nicotinamide, meanwhile, has decades of established use as a well-tolerated form of vitamin B3, distinct from nicotinic acid, which is more commonly associated with the flushing response at high doses.

The Bottom Line

You do not need an IV to meaningfully support your body's NAD+ levels. Multiple randomised, placebo-controlled human trials confirm that oral NAD+ precursors, specifically nicotinamide riboside and nicotinamide, produce measurable, dose-dependent, and sustained increases in whole-blood NAD+, along with downstream anti-inflammatory and DNA-repair benefits, all through a daily capsule rather than a clinical infusion.

The case for IV NAD+ therapy rests heavily on blood-level bioavailability, but the evidence for what actually matters sustained cellular NAD+ availability over time is strongest in the oral precursor research, precisely because it's designed around consistent, repeatable daily use rather than a single high-concentration session.

Precision-calibrated NAD+ support doesn't require a needle; it requires a scientifically architected daily protocol built on complementary precursor pathways. Explore the doctor-formulated, third-party tested longevity formulation engineered at Longevita.

FAQs

1. Can oral supplements really raise NAD+ levels as effectively as an IV?

Oral NAD+ precursors can't match the near-complete blood bioavailability of an IV in a single session, but clinical trials show they produce meaningful, sustained increases in whole-blood NAD+ over weeks of daily use, including up to a 142% rise with nicotinamide riboside chloride at higher doses. What matters more for long-term cellular support is sustained NAD+ availability over time, which repeat-dose oral trials are specifically designed to measure.

2. How long does it take for oral NAD+ precursors to work?

Clinical trial data show measurable increases in whole-blood NAD+ within two weeks of daily nicotinamide riboside supplementation, with levels maintained for the remainder of the study period through continued daily dosing.

3. Are NAD+ precursor supplements safe for daily long-term use?

Human trials support daily use. An 8-week randomised, placebo-controlled trial of nicotinamide riboside chloride reported no significant difference in adverse events compared to placebo, even at doses up to 1,000 mg per day, with stable blood lipids throughout.

4. What ingredients does Longevita use to support NAD+?

Longevita's formulation includes both nicotinamide riboside and niacinamide (nicotinamide) as NAD+ precursors, alongside polyphenols like pterostilbene and trans-resveratrol for AMPK support, and antioxidants including CoQ10 and lutein, combined in a single daily capsule formulated by a surgeon and longevity specialist.

References

Benavente, C.A. et al. (2012) 'Cellular NAD Replenishment Confers Marked Neuroprotection against UV-Induced Cell Death', PLOS ONE, 7(7), e42276.

Conze, D., Brenner, C. & Kruger, C.L. (2019) 'Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomised, double-blind, placebo-controlled clinical trial of healthy overweight adults', Scientific Reports, 9, Article 9772.

Covarrubias, A.J., Perrone, R., Grozio, A. & Verdin, E. (2020/2021) 'NAD+ metabolism and its roles in cellular processes during ageing', Nature Reviews Molecular Cell Biology, 22, pp. 119–141.

Deane, C.S. et al. (2024) 'Nicotinic acid supplementation and skeletal muscle mitochondrial respiration in older men'.

Elhassan, Y.S. et al. (2019) 'Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures', Cell Reports, 28(7), pp. 1717–1728.

Fang, E.F. et al. (2017) 'NAD+ in Ageing: Molecular Mechanisms and Translational Implications', Trends in Molecular Medicine, 23(10), pp. 899–916.

Makarov, M.V. et al. (2019) 'The chemistry of the vitamin B3 metabolome', Biochemical Society Transactions, 47(1), pp. 131–147.